In 2013, the European Commission launched the 7th Framework Program. Four projects were selected: A-ParaDDisE, KINDReD, NMTrypI and PDE4NPD.
As part of the negotiation process, the European Commission called for strong cooperation and synergy amongst the four projects in order to maximize the impact of the EU funds received.
The representatives of the four Consortia met in Paris, France, on December 5th 2013 in the occasion of the Paris-based DNDi meeting: 10 years of research in neglected infectious diseases. The meeting gave an opportunity for members to come together and discuss on potential areas of synergies.
All of the four Consortia have representatives of GSK (Glazo SmithKline) in their Scientific Advisory Board (SAB), and three of them (PDE4NPD, MNTrypI and KINDReD) share Dr. Eric Chatelain, Head of DNDi, as SAB Member,
The four Consortia met again on September 17th 2014 in the occasion of NMTrypI and KINDReD Consortium meeting in Porto, Portugal, and concrete Synergy activities have been planned. The EC Project Officer, Mr. Hannu Laang, and SAB members also joined the meeting.
The Coordinators of the "Synergy projects" meet regularly via teleconference every three monthes in order to assure the development of the activities.
SCOPE OF SYNERGIES
AREAS OF SYNERGIES
Kinetoplastid Drug Development
Scientific Coordinator: Dr. Jane MacDougall
Brief description: The KINDReD consortium has been drawn together from academia and industry to strengthen and advance the current drug development pipeline against Trypanosomatid diseases, Leishmaniasis, Human African trypanosomiasis and Chagas disease. KINDReD ambition is to bring much needed new drug candidates through the preclinical development process with the ultimate aim of gaining regulatory approval for initial phase I clinical trials for each of the three major trypanosomatid disease.
Anti-Parasite Drug Discovery in Epigenetics
Scientific Coordinator: Dr. Raymond J. Pierce
Brief description: The overall objective of the A-ParaDDisE project is to develop optimized epigenetic inhibitors for further testing and optimisation as drug candidates against the four parasites studied (S. mansoni, Leishmania, T. cruzi and Plasmodium sp.).
The Consortium will employ a target-based strategy for the development of novel drug leads against apigenetic targets in schistosomiasis, leishmaniasis, Chagas disease and malaria focusing on key histone modifying enzymes (HMEs), in particular those involved in acetylation/deacetylation and methylation/demethylation.
Phosphodiesterase Inhibitors for Neglected Parasitic Diseases
Scientific Coordinator: Dr. Rob Leurs
Brief description: The PDE4NPD Consortium was established to jointly find drugs for NPDs, targeting phosphodiesterases, in order to find and develop selective inhibitors. The Consortium focuses on three kinetoplastid diseases: human African trypanosomiasis (sleeping sickness), leishmaniasis and Chagas disease, and one major helminth disease: schistosomiasis (also known as biharzia or Snail fever). In order to optimally exploit the generated data, there will be a strong focus on developing an open innovative model for data sharing.